[Arrowhead Pharmaceuticals Q4 2026 Earnings Call] Arrowhead Posts $724M Net Loss as REDEMPLO Revenue Hits $6.6M; Flags $3B-$4B SHTG Opportunity and Q2 2027 Launch
Arrowhead Pharmaceuticals reported a fiscal 2026 net loss of $724.2M, down from $1.6M in 2025, with revenue at $450.8M, a 45.6% decrease. REDEMPLO (plozasiran) generated $6.6M in net product revenue. The company aims for a Q2 2027 launch of its SHTG indication, targeting $3B-$4B in annual sales. Management expects growth despite challenges in prescription conversion and payer coverage.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh quantitative data on loss magnitude, revenue decline, and pipeline milestones, informing valuation adjustments.
Market read
The report delivers the first detailed FY2026 financials and pipeline outlook, prompting immediate reassessment of Arrowhead's valuation.
What to watch
Strong payer coverage and expanding prescriber base for REDEMPLO could accelerate revenue beyond current guidance.
Background
Arrowhead transitioned from a pure science company to a commercial-stage biotech with its first product REDEMPLO and a pipeline targeting severe hypertriglyceridemia.
Ticker impact
Arrowhead Pharmaceuticals reported FY2026 Q4 results with a $724M net loss, $6.6M REDEMPLO revenue and outlined a $3B-$4B SHTG market opportunity.
likely pressure as the market prices in the large net loss and uncertainty around upcoming product launches
The disclosed loss and lack of guidance are fresh primary data; investors typically react negatively to unexpected earnings deficits, while future product potential is speculative.
Market effects
Highlights the financial risk and capital intensity of RNAi therapeutics, potentially affecting peer biotech valuations.
U.S. biotech sector may see modest pullback; European markets less affected.
Limited to biotech investors; no broad market impact.
Counterpoint
Long investors may view the $724M loss as a temporary cash burn supporting a high‑growth pipeline.
Key entities
- CompanyArrowhead Pharmaceuticals
NASDAQ‑listed RNAi therapeutics developer (ARWR).
- ProductREDEMPLO (plozasiran)
First commercial RNAi drug generating $6.6M net product revenue.
- Pipeline TargetSHTG
Severe hypertriglyceridemia indication with projected $3B-$4B market.
